TheraRadar
Landscape → Oncology

Triple Negative Breast Cancer Clinical Trial Landscape

Data updated: May 20, 2026

584 clinical trials tracked since 2008

Triple Negative Breast Cancer is being studied across 584 clinical trials registered since 2008, with 328 programs currently active. The competitive pipeline includes 42 active Phase 3 trials, 211 active Phase 2 trials, and 135 active Phase 1 trials. Top industry sponsors include Gilead, Novartis, AstraZeneca.

328 active
/
584 total (since 2008)
135
Phase 1 Active
272 total
211
Phase 2 Active
365 total
42
Phase 3 Active
65 total
3
Phase 4 Active
3 total

Top Industry Sponsors

Sorted by active Active Done Failed
Gilead 6 1 2
Novartis 3 7 5
AstraZeneca 3 3 0
AbbVie 3 1 1
Eli Lilly 3 0 2

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT06279364 RECRUITING
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=524
NCT05347134 ACTIVE NOT RECRUITING
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=254
NCT06393374 RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Merck Sharp & Dohme LLC n=1,530
NCT05633654 RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences n=1,514
NCT04595565 ACTIVE NOT RECRUITING
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
GBG Forschungs GmbH n=1,332

+ 60 more Phase 3 trials — see full database below

Triple Negative Breast Cancer — Trials Started by Year (last 10 years)

2016
25
2017
37
2018
41
2019
44
2020
41
2021
47
2022
54
2023
46
2024
78
2025
59
2026
45

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Gilead
9
Novartis
15
AstraZeneca
6
AbbVie
5
Eli Lilly
5
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
3
Mabwell (Shanghai) Bioscience Co., Ltd.
3
Exelixis
4
NiKang Therapeutics, Inc.
3
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
2

Active Trials by Phase

Phase 1
135
Phase 2
211
Phase 3
42
Phase 4
3

Enrollment Size Distribution

1-50
217
51-200
220
201-500
78
501-1k
35
1k+
9

All Industry Sponsors

Sorted by active Active Done Failed
Gilead 6 1 2
Novartis 3 7 5
AstraZeneca 3 3 0
AbbVie 3 1 1
Eli Lilly 3 0 2
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 3 0 0
Mabwell (Shanghai) Bioscience Co., Ltd. 3 0 0
Exelixis 2 1 1
NiKang Therapeutics, Inc. 2 0 1
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 2 0 0
BeBetter Med Inc 2 0 0
Sichuan Baili Pharmaceutical Co., Ltd. 2 0 0
Beijing Biotech 2 0 0
Radiopharm Theranostics, Ltd 2 0 0
Shanghai Henlius Biotech 2 0 0
NCT06279364 RECRUITING
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=524
NCT05347134 ACTIVE NOT RECRUITING
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. n=254
NCT07178730 NOT YET RECRUITING
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
West German Study Group n=765
NCT06393374 RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Merck Sharp & Dohme LLC n=1,530
NCT05633654 RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Gilead Sciences n=1,514
NCT07556848 NOT YET RECRUITING
A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd. n=356
NCT04595565 ACTIVE NOT RECRUITING
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
GBG Forschungs GmbH n=1,332
NCT07544056 NOT YET RECRUITING
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
BeBetter Med Inc n=446
NCT06382142 ACTIVE NOT RECRUITING
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
Sichuan Baili Pharmaceutical Co., Ltd. n=418
NCT07533123 RECRUITING
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd n=364
NCT05382299 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Gilead Sciences n=623
NCT05806060 RECRUITING
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Fudan University n=134
NCT07486687 NOT YET RECRUITING
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
The Netherlands Cancer Institute n=1,000
NCT06767527 RECRUITING
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Akeso n=416
NCT07407517 NOT YET RECRUITING
Adjuvant Intensification for LAR
Fudan University n=904
NCT06627712 RECRUITING
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
West China Hospital n=318
NCT06519370 ACTIVE NOT RECRUITING
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. n=350
NCT05909332 RECRUITING
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
Fudan University n=764
NCT07111832 RECRUITING
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=400
NCT04722978 RECRUITING
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
Sun Yat-Sen University Cancer Center n=228
NCT06081244 RECRUITING
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
West German Study Group n=348
NCT06732323 RECRUITING
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Qilu Pharmaceutical Co., Ltd. n=504
NCT05382286 ACTIVE NOT RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Gilead Sciences n=443
NCT06606730 RECRUITING
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
UNICANCER n=2,454
NCT05862064 RECRUITING
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
Fudan University n=606
NCT07021261 NOT YET RECRUITING
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients
Fudan University n=440
NCT05552001 RECRUITING
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
UNICANCER n=96
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT03562637 ACTIVE NOT RECRUITING
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
OBI Pharma, Inc n=575
NCT03168880 ACTIVE NOT RECRUITING
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer
Tata Memorial Hospital n=720
NCT06910072 NOT YET RECRUITING
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=32
NCT04296175 ACTIVE NOT RECRUITING
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)
Fudan University n=808
NCT03671044 RECRUITING
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Jina Pharmaceuticals Inc. n=657
NCT06419621 RECRUITING
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
Biotheus Inc. n=360
NCT06795503 NOT YET RECRUITING
Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
Fudan University n=1,462
NCT06533384 RECRUITING
PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
Guangdong Provincial People's Hospital n=310
NCT03281954 ACTIVE NOT RECRUITING
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NSABP Foundation Inc n=1,550
NCT05999149 RECRUITING
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
Fudan University n=424
NCT05760378 RECRUITING
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
Fudan University n=223
NCT02641847 ACTIVE NOT RECRUITING
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
Fudan University n=503
NCT05954442 RECRUITING
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Fudan University n=203
NCT04301739 NOT YET RECRUITING
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
Shanghai Henlius Biotech n=522
NCT04085276 COMPLETED
Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
Shanghai Junshi Bioscience Co., Ltd. n=531
NCT04148911 COMPLETED
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
Hoffmann-La Roche n=184
NCT01805076 COMPLETED
MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
Alliance for Clinical Trials in Oncology n=317
NCT05555706 COMPLETED
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Shanghai Jiaolian Drug Research and Development Co., Ltd n=62
NCT02819518 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Merck Sharp & Dohme LLC n=882
NCT03498716 TERMINATED
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Hoffmann-La Roche n=2,199
NCT04799249 COMPLETED
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
G1 Therapeutics, Inc. n=194
NCT05134194 TERMINATED
A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=1
NCT04613674 COMPLETED
A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Jiangsu HengRui Medicine Co., Ltd. n=441
NCT04177108 COMPLETED
A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche n=242
NCT03125902 COMPLETED
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Hoffmann-La Roche n=653
NCT03197935 COMPLETED
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
Hoffmann-La Roche n=333
NCT04335006 TERMINATED
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Jiangsu HengRui Medicine Co., Ltd. n=80
NCT03002103 SUSPENDED
A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer
SynCore Biotechnology Co., Ltd. n=420
NCT03674242 TERMINATED
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)
ERYtech Pharma n=27
NCT02425891 COMPLETED
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Hoffmann-La Roche n=902
NCT02555657 COMPLETED
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Merck Sharp & Dohme LLC n=622
NCT03055312 TERMINATED
Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
Sun Yat-sen University n=36
NCT02032277 COMPLETED
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
AbbVie n=634
NCT01216111 COMPLETED
Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)
Fudan University n=647
NCT03777579 SUSPENDED
A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=375
NCT01881230 COMPLETED
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Celgene n=191
NCT02225470 COMPLETED
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Eisai Co., Ltd. n=530

Full Triple Negative Breast Cancer Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only